Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis

This study has been completed.
Information provided by (Responsible Party):
Edith Vermeulen, Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier:
First received: November 23, 2010
Last updated: July 4, 2014
Last verified: July 2014
The purpose of this study is to evaluate the diagnostic potential of biomarkers for invasive pulmonary aspergillosis in exhaled breath condensate.

Invasive Pulmonary Aspergillosis

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Universitaire Ziekenhuizen Leuven:

Primary Outcome Measures:
  • The identification of biomarkers for invasive pulmonary aspergillosis (IPA) in exhaled breath condensate (EBC) [ Time Frame: 15 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA
exhaled breath condensate

Enrollment: 24
Study Start Date: January 2011
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Invasive pulmonary aspergillosis (IPA)
Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria) or putative IPA (Blot et al. Am J Respir Crit Care Med 2012)
Patients without signs of infection.

Detailed Description:
Invasive pulmonary aspergillosis (IPA) is a life-threatening infection in immunocompromised patients. The poor prognosis of the disease is partly attributed to difficulties encountered with the diagnosis of this infection. Invasive sampling procedures are often precluded in these patients. In addition, conventional diagnostic techniques lack sensitivity. Recently there has been increasing interest in the investigation of the lungs by noninvasive means including measurement of biomarkers in exhaled breath (e.g. NO) and those found in the cooled and condensed exhalate,termed EBC. It has been demonstrated that a measurable fraction of the EBC in healthy subjects is derived from aerosolized airway lining fluid. The presence of biomarkers for IPA will be investigated in EBC of patients with IPA, compared to controls.

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Hospitalized adult patients of the department of Hematology or Intensive Care Unit, University Hospital, Leuven, Belgium

Inclusion Criteria:

  • hospitalisation in the hematology or intensive care department
  • age > 16 years
  • informed consent
  • proven or probable IPA (EORTC/ MSG criteria)
  • galactomannan positivity in BAL or serum

Exclusion Criteria:

  • age < 16 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01247142

UZ Leuven
Leuven, Belgium, 3000
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
  More Information

Responsible Party: Edith Vermeulen, PhD fellow, Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier: NCT01247142     History of Changes
Other Study ID Numbers: S52756 
Study First Received: November 23, 2010
Last Updated: July 4, 2014
Health Authority: Belgium: Ethics Committee

Keywords provided by Universitaire Ziekenhuizen Leuven:
invasive pulmonary aspergillosis
exhaled breath condensate

Additional relevant MeSH terms:
Invasive Pulmonary Aspergillosis
Pulmonary Aspergillosis
Lung Diseases
Lung Diseases, Fungal
Respiratory Tract Diseases
Skin Diseases
Skin Diseases, Infectious

ClinicalTrials.gov processed this record on May 23, 2016